{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:45Z","timestamp":1788317685024,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103667","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:37:34Z","timestamp":1723145854000},"page":"103667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["TRAbectedin in adVanced rEtroperitoneal well differentiated\/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group"],"prefix":"10.1016","volume":"9","author":[{"given":"C.","family":"Fabbroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mazzocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brunello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.G.","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fatigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Alberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103667_bib1","series-title":"WHO Classification of Tumours Series","article-title":"Soft Tissue and Bone Tumours","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103667_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"De Pinieux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2024.103667_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2008.18.0802","article-title":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","volume":"27","author":"Bonvalot","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2008.17.8871","article-title":"Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients","volume":"27","author":"Gronchi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CCO.0000000000000377","article-title":"Treatment of retroperitoneal sarcoma: current standards and new developments","volume":"29","author":"Van Houdt","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/SLA.0000000000001149","article-title":"Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma","volume":"263","author":"Tan","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmoop.2024.103667_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","article-title":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multiinstitutional collaborative RPS working group","volume":"263","author":"Gronchi","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmoop.2024.103667_bib8","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1245\/s10434-021-09654-z","article-title":"Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group","volume":"28","author":"Swallow","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdy052","article-title":"Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103667_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1989.7.9.1208","article-title":"Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy","volume":"7","author":"Elias","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib11","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of Liposarcoma subtypes to chemotherapy","volume":"41","author":"Jones","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103667_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib13","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib14","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u0131a-del-Muro","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9829","key":"10.1016\/j.esmoop.2024.103667_bib15","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"10028","key":"10.1016\/j.esmoop.2024.103667_bib16","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103667_bib17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: what\u2019s new?","volume":"9","author":"D\u2019Incalci","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib19","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A\u00a0review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D\u2019Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2024.103667_bib20","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103667_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103667_bib22","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103667_bib23","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103667_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mds470","article-title":"Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy","volume":"24","author":"Penel","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103667_bib25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/SLA.0b013e3181b2468b","article-title":"Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule","volume":"250","author":"Park","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103667_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","article-title":"Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group","volume":"51","author":"Le Cesne","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103667_bib27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/cancers13051053","article-title":"Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, retrospective, multicenter study of the Italian Sarcoma Group","volume":"13","author":"Palmerini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103667_bib28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/cancers13061453","article-title":"Impact of pathological stratification on the clinical outcomes of advanced well-differentiated\/dedifferentiated liposarcoma treated with trabectedin","volume":"13","author":"Fabbroni","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:07:21Z","timestamp":1737331641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924014364"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103667","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRAbectedin in adVanced rEtroperitoneal well differentiated\/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103667"}}